share_log

Corvus Pharmaceuticals Announces Initiation Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis

Corvus Pharmaceuticals Announces Initiation Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis

Corvus Pharmaceuticals宣佈啓動索克利替尼治療特應性皮炎的安慰劑對照的1期臨床試驗
Benzinga ·  04/09 16:02

Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company's selective ITK inhibitor

特應性皮炎是該公司的選擇性ITK抑制劑索克利替尼臨床研究的第一個免疫疾病適應症

Corvus anticipates releasing initial clinical data from trial before year-end 2024

Corvus預計將在2024年年底之前發佈試驗的初步臨床數據

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論